IP Library Granted Patent US 11,572,396
Granted Patent B2
US 11,572,396 · App. 16/415,006 · Granted Feb 7, 2023

Therapeutic use of bone morphogenetic proteins

Inventors: Nicholas W. Morrell (Cambridge, GB); Wei Li (Cambridge, GB); Paul D Upton (Cambridge, GB)
Assignee: CAMBRIDGE ENTERPRISE LIMITED
C07K14/51A61K38/18A61K38/1875A61K38/00A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,572,396
App. No.
16/415,006
Granted
Feb 7, 2023
Kind
B2
Abstract

The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.

Claims (8)

1. A method of treating pulmonary arterial hypertension in a subject comprising administering to the subject a polypeptide which is a bone morphogenetic protein 9 (BMP9) variant having endothelial cell signaling activity and lacking osteogenic activity, wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of a substitution selected from the group consisting of F362A, D366A, I375A, L379A, 5402A, Y416A and Y418A.

2. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution F362A.

3. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution D366A.

4. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution I375A.

5. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution L379A.

6. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution 5402A.

7. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y416A.

8. The method of claim 1 , wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of the substitution Y418A.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2026
From: COCOON SA LLC
To: APCINTEX LIMITED; JANPIX LIMITED; CAPELLA BIOSCIENCE LTD; LOCKBODY THERAPEUTICS LTD; ULTRAHUMAN TWO LIMITED; ULTRAHUMAN FOUR LIMITED; MORPHOGEN-IX LIMITED; OREXIA THERAPEUTICS LIMITED; CARDIOKINE BIOPHARMA LLC; CENTESSA BIOSCIENCES, INC; PEARLRIVER BIO GMBH; Z FACTOR LIMITED
Reel/Frame 075737/0001 →
Priority Claims (1)
GB 1412290 · Jul 10, 2014 · national
Continuity (2)
Continuation 15324864
Related Publication 20190359668A1 · Nov 28, 2019